We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A high dose of Novartis' Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate/IND/GLY/MF) significantly reduced asthma exacerbations compared to a medium dose, shows a new analysis.